Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > For Any Stk On Halt

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Nov 11, 2020 6:52am

333 Views

Post# 31875997

For Any Stk On Halt

Stockhunter .... on Sedar under new filings .... this is where I keep an eye when any stk that is on halt .... in new filings when you look up the company of interest you can see the reasons why ... as issues are cleared or complete they bring current .... glta

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities